Last reviewed 2026-04-20 · How we verify

Qiv (qiv)

Pfizer's QIV is a marketed influenza vaccine preventing A(H1N1)pdm09, A(H3N2), and influenza B viruses. It has 100 trials and 302 publications. The vaccine generated $62.6B in revenue. QIV's mechanism involves preventing influenza viruses from infecting cells. This is crucial for preventing influenza-related complications. QIV's commercial significance lies in its widespread use during flu seasons. Pfizer continues to develop its pipeline, including updates to QIV.

At a glance

Approved indications

• Influenza prevention
• Prevention of influenza A virus, A(H1N1)pdm09, A(H3N2), and influenza B viruses

Common side effects

• Pain
• Irritability
• Injection site pain (PAIN)
• Fatigue (FATIGUE)
• Somnolence
• Nasopharyngitis
• Headache (HEADACHE)
• Decreased appetite
• Upper respiratory tract infection
• Erythema
• Pyrexia
• Injection site pain

Drug interactions

• Live, inactivated influenza vaccine
• Live attenuated influenza vaccine
• Other vaccines
• Immunoglobulin
• Thrombolytic agents
• Anticoagulants
• Antiplatelet agents
• NSAIDs
• Aspirin
• Warfarin
• Heparin
• Dabigatran

Key clinical trials

• Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
• A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
• A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
• A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
• Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Qiv CI brief — competitive landscape report
• Qiv updates RSS · CI watch RSS
• Pfizer portfolio CI